US pharmaceutical industry intermediaries defend their role

Pharmacy benefit managers defended their roles in a Congressional hearing amid accusations of promoting expensive treatments. Executives claimed their models save money, while a report highlighted anti-competitive practices and high drug prices.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here